1. Home
  2. WDAY vs ICUCW Comparison

WDAY vs ICUCW Comparison

Compare WDAY & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WDAY
  • ICUCW
  • Stock Information
  • Founded
  • WDAY 2005
  • ICUCW N/A
  • Country
  • WDAY United States
  • ICUCW United States
  • Employees
  • WDAY N/A
  • ICUCW 19
  • Industry
  • WDAY EDP Services
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • WDAY Technology
  • ICUCW Health Care
  • Exchange
  • WDAY Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • WDAY N/A
  • ICUCW N/A
  • IPO Year
  • WDAY 2012
  • ICUCW 2021
  • Fundamental
  • Price
  • WDAY $225.79
  • ICUCW $0.04
  • Analyst Decision
  • WDAY Buy
  • ICUCW
  • Analyst Count
  • WDAY 27
  • ICUCW 0
  • Target Price
  • WDAY $299.73
  • ICUCW N/A
  • AVG Volume (30 Days)
  • WDAY 2.9M
  • ICUCW N/A
  • Earning Date
  • WDAY 08-21-2025
  • ICUCW N/A
  • Dividend Yield
  • WDAY N/A
  • ICUCW N/A
  • EPS Growth
  • WDAY N/A
  • ICUCW N/A
  • EPS
  • WDAY 1.81
  • ICUCW N/A
  • Revenue
  • WDAY $8,696,000,000.00
  • ICUCW N/A
  • Revenue This Year
  • WDAY $14.87
  • ICUCW N/A
  • Revenue Next Year
  • WDAY $13.05
  • ICUCW N/A
  • P/E Ratio
  • WDAY $122.53
  • ICUCW N/A
  • Revenue Growth
  • WDAY 14.95
  • ICUCW N/A
  • 52 Week Low
  • WDAY $205.33
  • ICUCW N/A
  • 52 Week High
  • WDAY $294.00
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • WDAY 45.71
  • ICUCW N/A
  • Support Level
  • WDAY $206.77
  • ICUCW N/A
  • Resistance Level
  • WDAY $223.27
  • ICUCW N/A
  • Average True Range (ATR)
  • WDAY 6.65
  • ICUCW 0.00
  • MACD
  • WDAY -0.25
  • ICUCW 0.00
  • Stochastic Oscillator
  • WDAY 50.49
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: